The Effect of Alginate Encapsulated Supplements on Athletic Performance and Recovery

NCT ID: NCT06165393

Last Updated: 2023-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-11

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endurance sport is often characterized by high training loads and significant metabolic demands, including depletion of endogenous fuel stores (e.g. liver and muscle glycogen) and damage to the skeletal muscle proteins. Nutritional interventions that enhance the restoration of endogenous fuel stores and improve muscle damage repair have received a lot of attention. The primary aim of this project is to clinically test the effect of alginate encapsulation technology on performance. Furthermore, we will investigate the substrate utilization profile during exercise and subsequent recovery.

The encapsulation technology presents a nutrient delivery solution, which results in a sustained or slow-release of the nutrients encapsulated. Thus, potentially optimizing the digestion and absorption by promoting an easy ingestion of high concentrations of fx carbohydrates without negatively affecting the gastrointestinal comfort.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Athletic Performance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Slow-release CHO-AA

Alginate encapsulated Carbohydrates and Amino Acids

Group Type EXPERIMENTAL

Slow-release CHO-AA

Intervention Type DIETARY_SUPPLEMENT

Slow-release CHO-AA, alginate encapsulated

Slow-release CHO

Alginate encapsulated Carbohydrates

Group Type EXPERIMENTAL

Slow-release CHO

Intervention Type DIETARY_SUPPLEMENT

Slow-release CHO, alginate encapsulated

CHO

Carbohydrates only

Group Type ACTIVE_COMPARATOR

CHO

Intervention Type DIETARY_SUPPLEMENT

Carbohydrate-only, control

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Slow-release CHO-AA

Slow-release CHO-AA, alginate encapsulated

Intervention Type DIETARY_SUPPLEMENT

Slow-release CHO

Slow-release CHO, alginate encapsulated

Intervention Type DIETARY_SUPPLEMENT

CHO

Carbohydrate-only, control

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* males between 18-50 years of age
* moderate to trained individuals with a VO2max \> 50 ml/min/kg
* accustumed to exercising on a bike
* healthy volunteers

Exclusion Criteria

* persons diagnosed with metabolic diseases (i.e. Type 2 Diabetes) which relates to the carbohydrate metabolism.
* persons ingesting prescribed drugs/medicin, supplements or a special diet (i.e. low carbohydrate), which might affect the glycogen synthesis and/or performance.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Innovation Fund Denmark

INDIV

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Per Bendix Jeppesen

Associate. Prof, PhD.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Per Bendix Jeppesen

Aarhus N, , Denmark

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Per B Jeppesen, PhD

Role: CONTACT

Phone: +4528151877

Email: [email protected]

Lotte L Nielsen, M.Sc.

Role: CONTACT

Phone: +4522995827

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Per B Jeppesen, Ph.d

Role: primary

Lotte L Nielsen

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SWAP AU

Identifier Type: -

Identifier Source: org_study_id